Astra Industrial Group announces its Interim Financial Results for the Period Ending on 2022-09-30 ( Nine Months )

02 November 2022 08:10 AM

Default Company 1212.O 0.00% 0.00 0.00

Element List	Current Quarter	Similar quarter for previous year	%Change	Previous Quarter	% Change
Sales/Revenue	622,067,121	611,990,489	1.65	608,544,428	2.22
Gross Profit (Loss)	219,942,168	243,176,125	-9.55	225,761,071	-2.58
Operational Profit (Loss)	76,510,835	71,849,086	6.49	91,400,602	-16.29
Net Profit (Loss) after Zakat and Tax	70,865,145	45,373,403	56.18	243,096,412	-70.85
Total Comprehensive Income	70,989,680	43,208,880	64.29	238,228,033	-70.2
All figures are in (Actual) Saudi Arabia, Riyals

Element List	Current Period	Similar period for previous year	%Change
Sales/Revenue	1,865,130,534	1,739,623,541	7.21
Gross Profit (Loss)	719,580,291	706,557,987	1.84
Operational Profit (Loss)	263,217,470	260,075,244	1.21
Net Profit (Loss) after Zakat and Tax	388,651,783	150,579,006	158.1
Total Comprehensive Income	383,941,378	129,734,673	195.94
Total Share Holders Equity (after Deducting Minority Equity)	1,715,582,380	1,395,581,237	22.93
Profit (Loss) per Share	4.86	1.88
All figures are in (Actual) Saudi Arabia, Riyals

Element List	Explanation
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is	Net profit increases in general due to: 1. Decrease in selling and distribution expenses in the Pharmaceuticals sector 2. Decrease in general and administrative expenses in the following sectors: a) Pharmaceuticals b) Other 3. Increase in other income in the following sectors: c) Pharmaceuticals d) Other 4. Decrease in loss from discontinued operation While noting that there is decrease in gross profit in the Pharmaceuticals sector.
The reason of the increase (decrease) in the net profit during the current quarter compared to the previous quarter of the current year is	Net profit decrease in general due to: 1. Previous quarter included gain from discontinued operation 2. Decrease in gross profit in the following sectors: a) Specialty chemical b) Pharmaceuticals Gross profit decrease was partially offset by increase in gross profit in power and steel sector. 3. Increase in general and administrative expenses in the following sectors: a) Specialty chemical b) Pharmaceuticals 4. Increase in provision for impairment of financial assets expense in the following sectors: a) Pharmaceuticals b) Power and steel While noting that there is increase in other income in Pharmaceuticals and Other sector.
The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is	Net profit increases in general due to: 1. Gain from discontinued operation 2. Decrease in other expenses in pharmaceuticals sector. 3. Increase in sales and gross profit in the following sectors: a) Specialty chemical b) Pharmaceuticals 4. Decrease in provision for impairment of financial assets in all sectors. While noting that there is increase in selling and distribution expenses and general and administrative expenses in pharmaceuticals sector.
Statement of the type of external auditor's report	Unmodified conclusion
Reclassification of Comparison Items	Certain comparative figures for the previous period have been reclassified to be consistent with the presentation of the current period.
Additional Information	1. Net Shareholders’ Equity at the end of the period was SR 1,714,921,175 /- compared to SR 1,448,185,342 /- at the end of the similar period last year with an increase of 18%. 2. With the completion of the sale of Al Anmaa during the nine month period, the financial results and statements of Al Tanmiya were accounted for in accordance with IFRS requirements. Please refer to Note 13 of the condensed interim consolidated financial statements for further details.

Comments